Institutions / Caligan Partners LP
Caligan Partners LP
CIK 1727492 · Institution · as of Dec 31, 2025
Portfolio value
$1.09B
Positions
20
As of
Dec 31, 2025
Top holdings
Dec 31, 2025
| Company | Value | % of portfolio |
|---|---|---|
| Liquidia CorpLQDA | $280.02M | 25.6% |
| Abivax SA | $195.80M | 17.9% |
| Revolution Medicines, Inc. | $102.26M | 9.4% |
| Mineralys Therapeutics IncMLYS | $100.62M | 9.2% |
| Vaxcyte, Inc. | $78.66M | 7.2% |
| Exelixis, Inc. | $68.08M | 6.2% |
| ADMA Biologics Inc | $54.95M | 5.0% |
| Tango Therapeutics, Inc. | $33.05M | 3.0% |
| Inhibrx Biosciences, Inc. | $25.56M | 2.3% |
| Tyra Biosciences, Inc. | $24.82M | 2.3% |
| Xenon Pharmaceuticals Inc. | $24.64M | 2.3% |
| Maze Therapeutics, Inc. | $22.79M | 2.1% |
| Rapt Therapeutics Inc | $21.83M | 2.0% |
| Avalo Therapeutics, Inc. | $16.01M | 1.5% |
| Anika Therapeutics, Inc. | $13.79M | 1.3% |
| Vor Biopharma Inc. | $9.96M | 0.9% |
| Inventiva SA | $9.30M | 0.9% |
| Verrica Pharmaceuticals Inc.VRCA | $7.68M | 0.7% |
| Spruce Biosciences, Inc.SPRB | $1.79M | 0.2% |
| Eledon Pharmaceuticals, Inc. | $839.5K | 0.1% |
Activity
Dec 31, 2025
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.